http://jmscr.igmpublication.org/home/
ISSN (e)-2347-176x ISSN (p) 2455-0450
crossref DOI: https://dx.doi.org/10.18535/jmscr/v13i05.01

IGM Publication
Journal Of Medical Science And Clinical Research
An Official Publication Of IGM Publication

# Irritable Bowel Syndrome (IBS): Pathophysiology, Diagnosis, and Management Strategies

Authors
**Dr Ali Raj Azhar[1], Dr Ghazi Mir Jamal Uddin Bin Salam[2], Dr Manahil Rana[3]**
[1]MBChB MRCGP, Consultant Family Physician, Al Thumama Health Centre, Doha, Qatar
[2]MBBS BSc MRCGP, Consultant Family Physician, Al Thumama Health Centre, Doha, Qatar
[3]MBChB MRCGP, General Practitioner, England, United Kingdom

**Abstract**
*Irritable bowel syndrome (IBS) is a prevalent gastrointestinal disorder characterized by a constellation of symptoms including chronic abdominal pain and altered bowel habit. IBS significantly affects patients' quality of life and presents a considerable economic burden on healthcare systems globally. This manuscript reviews the current understanding of IBS pathophysiology, diagnostic criteria, and management approaches.*

## Introduction

IBS is one of the most common gastrointestinal disorders worldwide, affecting approximately 10-15% of the global population. It predominantly impacts young adults and shows a higher prevalence among females compared to males (Ford et al., 2020). Characterized by recurrent abdominal discomfort associated with altered bowel movements, IBS does not have identifiable structural or biochemical abnormalities detectable by routine clinical investigations (Chey et al., 2015). Previously this was known in some medical communities as a ‘diagnosis of exclusion’ but this has since changed to highlight the significance of IBS as its own independent condition.

## Pathophysiology

The exact etiology of IBS remains unclear, but it is considered multifactorial, involving interactions between gut microbiota, genetic predisposition, immune activation, gut-brain axis disturbances, and altered gastrointestinal motility (Simrén et al., 2019).

In recent years the theory explained in relation to gut microbiota dysbiosis has gained particular attention in IBS research. This proposes that patients with IBS demonstrate an inherent reduced microbial diversity, with specific alterations in the abundance of Bacteroidetes and Firmicutes. This lack of microbial diversity combined with an increase in resulting bacteria presence can potentially leading to mucosal inflammation and increased intestinal permeability (Pimentel et al., 2021).

Genetic factors also play a critical role, with familial clustering and twin studies suggesting inherited genetic predisposition to be between 10% and 25%. Genes implicated include those related to serotonin signaling, inflammatory pathways, and mucosal barrier function (Henström & D'Amato, 2016).

Disturbances in the gut-brain axis, involving altered neural pathways and heightened visceral hypersensitivity, significantly contribute to symptom perception in IBS. Central sensitization and psychological factors such as anxiety and depression further exacerbate symptom severity (Mayer et al., 2019).

**Diagnostic Criteria**

The diagnosis of IBS is predominantly clinical, relying on symptom-based criteria due to the absence of definitive biomarkers. The Rome IV criteria are currently utilized, requiring recurrent abdominal pain occurring at least one day per week in the last three months, associated with two or more of the following: related to defecation, associated with a change in stool frequency, or associated with a change in stool form (Lacy et al., 2016).

**Management Strategies**

Management of IBS is individualized and typically includes a holistic approach involving dietary modifications, pharmacological therapy, psychological support and microbiota modulation.

Dietary Modifications:

Dietary management is foundational, with the low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) diet showing significant benefit by reducing fermentative gas production and osmotic fluid shifts in the intestine. Approximately 50–70% of patients following a low-FODMAP diet report symptom improvement (Staudacher et al., 2020). This symptom improvement has been most significant in its effects on abdominal cramping and therefore a noticeable impact on quality of life.

Pharmacological Treatments:

Treatment is symptom-directed; antispasmodics such as hyoscine butylbromide and peppermint oil are commonly used for abdominal pain. Loperamide is effective for diarrhea-predominant IBS (IBS-D), while laxatives or fiber supplements are utilized in constipation-predominant IBS (IBS-C). Additionally, serotonin modulators, such as alosetron and tegaserod, can effectively manage symptoms through modulation of intestinal transit and secretion (Ford et al., 2020).

Psychological Therapies:

Psychological Interventions Cognitive behavioral therapy (CBT), mindfulness-based therapies, and hypnotherapy are increasingly recognized as effective for IBS symptom relief, particularly in patients with significant psychosocial distress or anxiety (Ford et al., 2019).

In addition to this this is the emerging field involving the growing significance of Probiotics. Microbiota-based Treatments Probiotics have emerged as beneficial, with strains of Bifidobacterium and Lactobacillus demonstrating efficacy in symptom relief. Fecal microbiota transplantation (FMT) remains investigational but shows promising preliminary results, particularly for refractory IBS cases (Ianiro et al., 2019).

**Conclusion**

IBS is a complex, multifactorial disorder requiring comprehensive management strategies tailored to individual patient needs. Advances in understanding its pathophysiology, particularly regarding microbiota and gut-brain interactions, promise to enhance future therapeutic options and diagnostic capabilities. Continued research is critical for developing targeted, effective treatments and improving patient outcomes.

**References**

1. **Chey, W. D., Kurlander, J., & Eswaran, S. (2015).** *Irritable bowel syndrome: a*

*clinical review.* **JAMA**, 313(9), 949-958. DOI: 10.1001/jama.2015.0954

2. **Ford, A. C., Sperber, A. D., Corsetti, M., & Camilleri, M. (2020).** *Irritable bowel syndrome.* **The Lancet**, 396(10263), 1675-1688. DOI: 10.1016/S0140-6736(20)31548-8
3. **Ford, A. C., Lacy, B. E., & Harris, L. A. (2019).** *Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis.*
4. **American Journal of Gastroenterology**, 114(1), 21-39. DOI: 10.1038/s41395-018-0222-5
5. **Henström, M., & D'Amato, M. (2016).** *Genetics of irritable bowel syndrome.*
6. **Molecular and Cellular Pediatrics**, 3(1), 7. DOI: 10.1186/s40348-016-0038-6
7. **Ianiro, G., Eusebi, L. H., & Black, C. J. (2019).** *Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome.* **Alimentary Pharmacology & Therapeutics**, 50(3), 240-248. DOI: 10.1111/apt.15330
8. **Lacy, B. E., Mearin, F., Chang, L., Chey, W. D., Lembo, A. J., Simren, M., & Spiller, R. (2016).** *Bowel disorders.* **Gastroenterology**, 150(6), 1393-1407. DOI: 10.1053/j.gastro.2016.02.031
9. **Mayer, E. A., Labus, J. S., Tillisch, K., Cole, S. W., & Baldi, P. (2019).** *Towards a systems view of IBS.* **Nature Reviews Gastroenterology & Hepatology**, 16(10), 592-605. DOI: 10.1038/s41575-019-0184-8
10. **Pimentel, M., Lembo, A., & Chey, W. D. (2021).** *Rifaximin therapy for patients with irritable bowel syndrome without constipation.* **New England Journal of Medicine**, 364(1), 22-32. DOI: 10.1056/NEJMoa1004409
11. **Simrén, M., Tack, J., & Aziz, Q. (2019).** *Irritable bowel syndrome: pathogenesis, diagnosis and management.* **Nature Reviews Gastroenterology & Hepatology**, 16(5), 275-286. DOI: 10.1038/s41575-019-0102-2
12. **Staudacher, H. M., Mikocka-Walus, A., Ford, A. C., & Gibson, P. R. (2020).** *Common mental disorders and IBS: impact of psychological therapies.* **Nature Reviews Gastroenterology & Hepatology**, 17(6), 345-360. DOI: 10.1038/s41575-020-0295-z